We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Catalent, Palatin Technologies Announce Agreement
News

Catalent, Palatin Technologies Announce Agreement

Catalent, Palatin Technologies Announce Agreement
News

Catalent, Palatin Technologies Announce Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Catalent, Palatin Technologies Announce Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Catalent Pharma Solutions has announced that it has reached a commercial supply agreement with Palatin Technologies, Inc., to support the global commercial product launch of Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD). Bremelanotide, an on-demand, subcutaneous injectable peptide melanocortin receptor agonist, is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women.

Phase 3 clinical trials are on-going, with a commercial launch anticipated in 2018. “We are pleased that Palatin has chosen to partner with Catalent to commercialize this new and innovative treatment,” commented Jonathan Arnold, Catalent’s Vice President and General Manager for Advanced Delivery Technologies.

“Catalent provides flexible manufacturing solutions to meet our customers’ unique program requirements, and our expertise in sterile filling, device and delivery technologies, combined with our packaging capabilities, will facilitate bringing this important product to market faster.”

“We selected Catalent as our partner because of their proven expertise in custom sterile manufacturing solutions, and their track record of successful new product introductions,” added Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin. “Catalent provides the infrastructure, technical expertise and flexibility to support commercialization of this novel product.”

The bremelanotide pen devices will be produced at Catalent's 265,000 sq. ft. Brussels, Belgium site, the company’s flagship sterile fill finish facility, with a syringe-filling capacity of over 100 million units.

Advertisement